These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32951510)

  • 21. Long-term health outcomes and cost-effectiveness of a computer-tailored physical activity intervention among people aged over fifty: modelling the results of a randomized controlled trial.
    Peels DA; Hoogenveen RR; Feenstra TL; Golsteijn RH; Bolman C; Mudde AN; Wendel-Vos GC; de Vries H; Lechner L
    BMC Public Health; 2014 Oct; 14():1099. PubMed ID: 25342517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What will the cardiovascular disease slowdown cost? Modelling the impact of CVD trends on dementia, disability, and economic costs in England and Wales from 2020-2029.
    Collins B; Bandosz P; Guzman-Castillo M; Pearson-Stuttard J; Stoye G; McCauley J; Ahmadi-Abhari S; Araghi M; Shipley MJ; Capewell S; French E; Brunner EJ; O'Flaherty M
    PLoS One; 2022; 17(6):e0268766. PubMed ID: 35767575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsimihodimos V; Diogo V; Karpouzos G; Papageorgiou G; Kourlaba G
    Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of a Stepwise Approach vs Standard Care for Diabetes Prevention in India.
    Islek D; Weber MB; Ranjit Mohan A; Mohan V; Staimez LR; Harish R; Narayan KMV; Laxy M; Ali MK
    JAMA Netw Open; 2020 Jul; 3(7):e207539. PubMed ID: 32725244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
    Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
    Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis.
    Losina E; Smith KC; Paltiel AD; Collins JE; Suter LG; Hunter DJ; Katz JN; Messier SP
    Arthritis Care Res (Hoboken); 2019 Jul; 71(7):855-864. PubMed ID: 30055077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness of using cognitive screening tests for detecting dementia and mild cognitive impairment in primary care.
    Tong T; Thokala P; McMillan B; Ghosh R; Brazier J
    Int J Geriatr Psychiatry; 2017 Dec; 32(12):1392-1400. PubMed ID: 27874210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of a health intervention program with risk reductions for getting demented: results of a Markov model in a Swedish/Finnish setting.
    Zhang Y; Kivipelto M; Solomon A; Wimo A
    J Alzheimers Dis; 2011; 26(4):735-44. PubMed ID: 21709377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice.
    Elliott RA; Tanajewski L; Gkountouras G; Avery AJ; Barber N; Mehta R; Boyd MJ; Latif A; Chuter A; Waring J
    Pharmacoeconomics; 2017 Dec; 35(12):1237-1255. PubMed ID: 28776320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes.
    Ackermann RT; Marrero DG; Hicks KA; Hoerger TJ; Sorensen S; Zhang P; Engelgau MM; Ratner RE; Herman WH
    Diabetes Care; 2006 Jun; 29(6):1237-41. PubMed ID: 16732002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cost-effectiveness modelling study of strategies to reduce risk of infection following primary hip replacement based on a systematic review.
    Graves N; Wloch C; Wilson J; Barnett A; Sutton A; Cooper N; Merollini K; McCreanor V; Cheng Q; Burn E; Lamagni T; Charlett A
    Health Technol Assess; 2016 Jul; 20(54):1-144. PubMed ID: 27468732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of a community-based cardiovascular disease prevention intervention in medically underserved rural areas.
    Wang H; Kenkel D; Graham ML; Paul LC; Folta SC; Nelson ME; Strogatz D; Seguin RA
    BMC Health Serv Res; 2019 May; 19(1):315. PubMed ID: 31096977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of a statewide public health intervention to reduce cardiovascular disease risk.
    Smith L; Atherly A; Campbell J; Flattery N; Coronel S; Krantz M
    BMC Public Health; 2019 Sep; 19(1):1234. PubMed ID: 31492118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimating the cost-effectiveness of salt reformulation and increasing access to leisure centres in England, with PRIMEtime CE model validation using the AdViSHE tool.
    Briggs ADM; Wolstenholme J; Scarborough P
    BMC Health Serv Res; 2019 Jul; 19(1):489. PubMed ID: 31307459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
    Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
    Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.